SEC Company Response from Rein Therapeutics, Inc. (RNTX) (CIK 0001420565) (RNTX) — May 10, 2019
Rein Therapeutics, Inc. (RNTX) (CIK 0001420565)
Date: May 10, 2019 · CIK: 0001420565 · Accession: 0001193125-19-144108
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231143
Letter
AILERON THERAPEUTICS, INC.
490 Arsenal Way, Suite 210
Watertown, MA 02472
May 10, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Aileron Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-231143
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aileron Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-231143) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on May 14, 2019, or as soon thereafter as practicable.
Very truly yours,
AILERON THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP AILERON THERAPEUTICS, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 May 10, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aileron Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-231143 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aileron Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-231143) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on May 14, 2019, or as soon thereafter as practicable. Very truly yours, AILERON THERAPEUTICS, INC. By: /s/ Donald V. Dougherty Name: Title: Donald V. Dougherty Senior Vice President, Chief Financial Officer cc: Stuart M. Falber Wilmer Cutler Pickering Hale and Dorr LLP